MY187748A - Compositions and method for maintaining/improving cognitive function - Google Patents

Compositions and method for maintaining/improving cognitive function

Info

Publication number
MY187748A
MY187748A MYUI2015001760A MYUI2015001760A MY187748A MY 187748 A MY187748 A MY 187748A MY UI2015001760 A MYUI2015001760 A MY UI2015001760A MY UI2015001760 A MYUI2015001760 A MY UI2015001760A MY 187748 A MY187748 A MY 187748A
Authority
MY
Malaysia
Prior art keywords
maintaining
derivative
salt
combinations
source
Prior art date
Application number
MYUI2015001760A
Inventor
Christopher Oliver
Attila Pataki
Original Assignee
Blackmores Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905441A external-priority patent/AU2012905441A0/en
Application filed by Blackmores Ltd filed Critical Blackmores Ltd
Publication of MY187748A publication Critical patent/MY187748A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions comprising a combination of: (i) one or more B vitamins or alternative form(s), derivative(s), or salt(s) thereof, or combinations thereof, and/or source(s) thereof; and (ii) phosphatidylserine, or alternative form(s), derivative(s), or salt(s) thereof, or combinations thereof, and/or source(s) thereof; and/or lipoic acid, or alternative form(s), derivative(s), or salt(s) thereof, or combinations thereof, and/or source(s) thereof, and/or methods of using the same combination for maintaining/improving cognitive function of adults including elderly adults and/or for maintaining/improving mood in ageing subjects and/or reducing risk markers of cardiovascular disease and/or genetic markers and/or biochemical markers associated with ageing. The compositions include, but are not limited to, dietary supplements e.g., nutritional supplements.
MYUI2015001760A 2012-12-11 2013-12-11 Compositions and method for maintaining/improving cognitive function MY187748A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012905441A AU2012905441A0 (en) 2012-12-11 Composition and method for maintaining/improving cognitive function
PCT/AU2013/001447 WO2014089620A1 (en) 2012-12-11 2013-12-11 Compositions and method for maintaining/improving cognitive function

Publications (1)

Publication Number Publication Date
MY187748A true MY187748A (en) 2021-10-18

Family

ID=50933582

Family Applications (1)

Application Number Title Priority Date Filing Date
MYUI2015001760A MY187748A (en) 2012-12-11 2013-12-11 Compositions and method for maintaining/improving cognitive function

Country Status (4)

Country Link
CN (1) CN104981244A (en)
AU (2) AU2013360021A1 (en)
MY (1) MY187748A (en)
WO (1) WO2014089620A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
CN107050073A (en) * 2017-04-27 2017-08-18 河南佳禾康生物食品科技有限公司 It is a kind of to strengthen memory, the health products for slowing down brain aging and preparation method thereof
PL422153A1 (en) * 2017-07-06 2019-01-14 Cięciara Mariusz Stable liquid composition containing vitamins and folic acid and application of the composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
DE10318045A1 (en) * 2003-04-17 2004-11-04 Basf Ag Stable ammonium salts of alpha-lipoic acid, its production and use
US20090143433A1 (en) * 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
US20090215885A1 (en) * 2005-05-10 2009-08-27 Brainsavers Llc Antioxidant Food Composition and Methods and Uses Thereof
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
CN101874630A (en) * 2010-05-24 2010-11-03 崔晓廷 Brain health-care product for improving memory and cognitive power
EP2588198A1 (en) * 2010-07-01 2013-05-08 Isis Innovation Limited Treatment of cognitive disorders

Also Published As

Publication number Publication date
WO2014089620A1 (en) 2014-06-19
AU2013360021A1 (en) 2015-07-09
AU2018101460A4 (en) 2018-10-25
CN104981244A (en) 2015-10-14

Similar Documents

Publication Publication Date Title
EP2576578A4 (en) Polymorphs of 2'-o-fucosyllactose and producing thereof
WO2014099165A3 (en) Zinc amino acid complex with cysteine
MY166016A (en) Infant nutrition for improving fatty acid composition of brain membranes
EA201070419A1 (en) COMPOSITION FOR REGULATING METABOLISM OF LIPIDS
WO2014057362A3 (en) Omega -3 compositions
EP2717698A4 (en) Antihistamines combined with dietary supplements for improved health
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
MX340147B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
MX2015007584A (en) Triheptanoin for the treatment of glucose transporter 1 deficiency.
MX2018002546A (en) Compositions comprising an urolithin compound.
EA201401117A1 (en) COMPOSITIONS CONTAINING PROBIOTICS AND COMPLEX OF BEE POULTRY / CLAY, METHOD OF THEIR PREPARATION AND THEIR APPLICATION IN FOOD AND THERAPY
BR112013028820A2 (en) medicinal food for cognitive decline
PH12016500025A1 (en) Methods for promoting neuronal development and/or health
EA201491426A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHATIDILSERIN AND CURKUMIN
MY187748A (en) Compositions and method for maintaining/improving cognitive function
EP2709455A4 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
AU2011343331A8 (en) Compositions based on clay and bee pollen, method for preparing same, and nutritional and therapeutic uses thereof
ITTO20130819A1 (en) COMPOSITION BASED ON VEGETABLE EXTRACTS FOR CHECKING ALTERATE GLYCEMIA FOR FASTING AND / OR HEMATIC LIPIDS AND USING AS A FOOD SUPPLEMENT OR AS A MEDICINE.
WO2011139106A3 (en) Method for diagnosis of dementia by measuring concentration of pgcp in plasma
IN2013MU02025A (en)
WO2013064326A3 (en) Arjunolic acid for increasing the production of sebum
PL401911A1 (en) Use of the preparation with the immunoregulatory properties
MY181907A (en) Composition and methods for hyperhomocysteinemia
UA103141C2 (en) Use of anti-hsp60 antibodies as markers of immune safety of hemotransfusions in cardio-surgery of congenital heart diseases
PL398758A1 (en) Diphenyl phosphonic analogs of glutamic acid and their peptide derivatives, process for the preparation and use thereof